Anti-Human CCR4 (Mogamulizumab Biosimilar)
英诺赛图(InnoCyto)的 Anti-Human CCR4 (Mogamulizumab Biosimilar)(克隆 Mogamulizumab) 为人源 IgG1 抗体,靶向 CCR4(别名 CD194 等),适用于流式细胞术。提供 1 mg、5 mg、20 mg 规格,目录价 ¥1,695 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 Anti-Human CCR4 (Mogamulizumab Biosimilar)(克隆 Mogamulizumab) 为人源 IgG1 抗体,靶向 CCR4(别名 CD194 等),适用于流式细胞术。提供 1 mg、5 mg、20 mg 规格,目录价 ¥1,695 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
503801 | 1 mg | ¥1,695
503802 | 5 mg | ¥5,085
503803 | 20 mg | ¥16,950
Product Details
Product Description|Mogamulizumab Biosimilar, CCR4 Monoclonal Antibody
Regulatory Status|RUO
Species specificity|Human
Storage Conditions|4ºC
Maximal Shelf Life|12 months
See All Formats|Clone Mogamulizumab
Background Information
Mogamulizumab is a humanized monoclonal antibody belonging to the immunoglobulin G1 kappa (IgG1κ) subclass, engineered to specifically recognize and bind to the CC chemokine receptor 4 (CCR4). Structurally, Mogamulizumab is a glycoprotein with a molecular mass of approximately 149 kilodaltons (kDa). It consists of two identical heavy chains and two identical light chains joined by disulfide bonds, forming the typical Y-shaped antibody structure. Produced in mammalian expression systems such as Chinese Hamster Ovary (CHO) cells, it undergoes controlled post-translational modifications to ensure proper folding, stability, and glycosylation patterns essential for its biological function.
The variable regions of Mogamulizumab (the antigen-binding (Fab) fragments) contain complementarity-determining regions (CDRs) responsible for high-affinity recognition of CCR4, which is a seven-transmembrane G protein–coupled receptor expressed on specific subsets of immune cells. These CDRs were derived from murine antibody sequences and grafted onto a human IgG1 framework to preserve target specificity while minimizing nonhuman structural elements. Mogamulizumab is uniquely designed with a defucosylated Fc (fragment crystallizable) region, created through glycoengineering to remove fucose residues from the Fc-linked N-glycan at asparagine 297. This modification significantly enhances the antibody’s binding affinity to Fc gamma receptor IIIa (FcγRIIIa) on effector cells such as natural killer (NK) cells, thereby amplifying antibody-dependent cellular cytotoxicity (ADCC) in in vitro systems.
Functionally, upon binding to CCR4 on target cells, Mogamulizumab can trigger immune effector mechanisms such as ADCC and complement-dependent cytotoxicity (CDC), leading to targeted cell elimination in experimental models. Beyond its cytotoxic potential, CCR4 binding may alter receptor-mediated signaling and downstream chemotactic responses. The Fc–FcRn (neonatal Fc receptor) interaction provides extended serum half-life and molecular stability through recycling.
Data Sheets
Cat # Size Price Quantity 5038011 mg Add to Cart5038025 mg Add to Cart50380320 mg Add to Cart
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). Anti-Human CCR4 (Mogamulizumab Biosimilar)(503801)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/anti-human-ccr4-mogamulizumab-biosimilar.html.
TeleVM. (2026, November 12). Anti-Human CCR4 (Mogamulizumab Biosimilar)(503801). 产品目录. https://www.suprotek.cn/products/item/anti-human-ccr4-mogamulizumab-biosimilar.html
@misc{biocsp_item_anti_human_ccr4_mogamulizumab_biosimilar,
title = {Anti-Human CCR4 (Mogamulizumab Biosimilar)(503801)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/anti-human-ccr4-mogamulizumab-biosimilar.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源